Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), as of 2019, approximately 42.2 million people have died from acquired immunodeficiency syndrome (AIDS)-related illnesses since the start of the epidemic. Antiretroviral therapy (ART) has significantly reduced mortality, morbidit...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022
|
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.intimp.2022.108580 http://hdl.handle.net/11408/5027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), as of 2019, approximately 42.2
million people have died from acquired immunodeficiency syndrome (AIDS)-related illnesses since the start of
the epidemic. Antiretroviral therapy (ART) has significantly reduced mortality, morbidity, and incidence of the
human immunodeficiency virus (HIV)/AIDS-defining cancers, taming once-dreaded disease into a benign chronic
infection. Although the treatment has prolonged the patients’ survival, general HIV prevalence has increased and
this increase has dovetailed with an increasing incidence of Non-AIDS-defining cancers (NADCs) among people
living with HIV (PLWH). This is happening when new promising approaches in both oncology and HIV infection
are being developed. This review focuses on recent progress witnessed in immunotherapy approaches against
HIV-related, Non-AIDS-defining cancers (NADCs), and HIV infection |
|---|